Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Vasoactive intestinal peptide shapes first-trimester placenta trophoblast, vascular, and immune cell cooperation.

British journal of pharmacology | 2019

Extravillous trophoblast (EVT) cells are responsible for decidual stromal invasion, vascular transformation, and the recruitment and functional modulation of maternal leukocytes in the first-trimester pregnant uterus. An early disruption of EVT function leads to placental insufficiency underlying pregnancy complications such as preeclampsia and fetal growth restriction. Vasoactive intestinal peptide (VIP) is a vasodilating and immune modulatory factor synthesized by trophoblast cells. However, its role in first-trimester placenta has not been explored. Here, we tested the hypothesis that VIP is involved in first-trimester EVT outgrowth, spiral artery remodelling, balancing angiogenesis, and maintenance of immune homeostasis.

Pubmed ID: 30726565 RIS Download

Associated grants

  • Agency: Canadian Institutes for Health Research, International

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Goat anti-Mouse IgG (H+L) Secondary Antibody, HRP (antibody)

RRID:AB_2533947

This polyclonal secondary targets IgG (H+L)

View all literature mentions

CD56 (antibody)

RRID:AB_2282500

This monoclonal targets NCAM1

View all literature mentions

CD14 (antibody)

RRID:AB_2291249

This monoclonal targets CD14

View all literature mentions

CD31, Endothelial Cell (antibody)

RRID:AB_2114471

This monoclonal targets CD31

View all literature mentions

Monoclonal Mouse Anti Human Smooth Muscle Actin (antibody)

RRID:AB_2223500

This monoclonal targets Smooth Muscle Actin

View all literature mentions

IUPHAR/BPS Guide to Pharmacology (data or information resource)

RRID:SCR_013077

Portal and searchable database of pharmacological information. Information is presented at two levels, the initial view or landing pages for each target family provide expert-curated overviews of the key properties and the available selective ligands and tool compounds. For selected targets, more detailed introductory chapters for each family are available along with curated information on the pharmacological, physiological, structural, genetic and pathophysiogical properties of each target.

View all literature mentions

ImageJ (software resource)

RRID:SCR_003070

Open source Java based image processing software program designed for scientific multidimensional images. ImageJ has been transformed to ImageJ2 application to improve data engine to be sufficient to analyze modern datasets.

View all literature mentions

GraphPad Prism (software resource)

RRID:SCR_002798

Statistical analysis software that combines scientific graphing, comprehensive curve fitting (nonlinear regression), understandable statistics, and data organization. Designed for biological research applications in pharmacology, physiology, and other biological fields for data analysis, hypothesis testing, and modeling.

View all literature mentions

Swan 71 (cell line)

RRID:CVCL_D855

Cell line Swan 71 is a Telomerase immortalized cell line with a species of origin Homo sapiens (Human)

View all literature mentions

BeWo (cell line)

RRID:CVCL_0044

Cell line BeWo is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

IUPHAR/BPS Guide to Pharmacology (data or information resource)

RRID:SCR_013077

Portal and searchable database of pharmacological information. Information is presented at two levels, the initial view or landing pages for each target family provide expert-curated overviews of the key properties and the available selective ligands and tool compounds. For selected targets, more detailed introductory chapters for each family are available along with curated information on the pharmacological, physiological, structural, genetic and pathophysiogical properties of each target.

View all literature mentions